Pfizer Indiplon “Refuse To File” For eNDA May Stem From Shift In FDA Oversight
Executive SummaryFDA's shift of responsibilities for Pfizer/Neurocrine's insomnia drug indiplon between review divisions may have led to the agency's delay in accepting the NDA
You may also be interested in...
Technical deficiencies foil the resubmission of Chelsea Therapeutics’ Northera. The company thinks it can resolve the problems quickly and some analysts expect a relatively short delay of one or two months to the user fee date.